Literature DB >> 17336372

Excess of early onset multiple myeloma in endometrial cancer probands and their relatives suggests common susceptibility.

Israel Zighelboim1, Sheri Babb, Feng Gao, Matthew A Powell, David G Mutch, Paul J Goodfellow.   

Abstract

OBJECTIVE: Determine whether there is an association between uterine cancer and multiple myeloma.
METHODS: Data on second malignancies were obtained for 368 uterine corpus cancer patients treated between 1992 and 2005. Detailed family histories were devised for 192 probands. Diagnoses of multiple myelomas, lymphomas and leukemias in family members were medical record verified. The frequency of multiple myeloma among uterine cancer patients was compared to the female age-adjusted incidence rate of multiple myeloma obtained from the SEER database. The crude rate of multiple myeloma (as well as Hodgkin's, non-Hodgkin's lymphomas and leukemias) among first-degree relatives of patients with uterine cancer was compared to the age-adjusted incidence rate of multiple myeloma in the general population. Descriptive statistics were used to evaluate disease and cohort characteristics. A P value less than 0.05 was considered statistically significant.
RESULTS: Two of 368 uterine cancer patients were also diagnosed with multiple myeloma, both at age 50. The observed incidence of multiple myeloma in this cohort (543 per 100,000; 95% CI: 66-1962 per 100,000) represents a 120-fold increase based on predicted incidence (P=0.00014). The frequency of multiple myeloma in first-degree relatives was 2/1351 (148 per 100,000; 95% CI: 14.8-533 per 100,000) which represents a 27-fold increase compared to the general population (P=0.0026). The frequencies of leukemias and lymphomas in these family members on the other hand were not significantly increased (P=0.152 and P=0.218).
CONCLUSION: This specific excess frequency of early onset multiple myeloma in endometrial cancer probands and their relatives suggests shared susceptibility.

Entities:  

Mesh:

Year:  2007        PMID: 17336372      PMCID: PMC2577217          DOI: 10.1016/j.ygyno.2006.12.022

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  [Association of multiple myeloma and solid neoplasms: analysis of 13 cases].

Authors:  J A Todolí Parra; C Campo López; A Segura Huerta; R Alonso Estellés; E Saro Pérez; A Torrego Giménez; A Santaballa Bertrán; M Pastor Borgoñón; J R Calabuig Alborch
Journal:  Rev Clin Esp       Date:  1999-11       Impact factor: 1.556

2.  Analysis of PTEN deletions and mutations in multiple myeloma.

Authors:  Hong Chang; Xiao Ying Qi; Jaime Claudio; Lihua Zhuang; Bruce Patterson; A Keith Stewart
Journal:  Leuk Res       Date:  2005-08-19       Impact factor: 3.156

3.  Germline CDKN2A mutation implicated in predisposition to multiple myeloma.

Authors:  D Dilworth; L Liu; A K Stewart; J R Berenson; N Lassam; D Hogg
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

4.  A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group.

Authors:  S B Gruber; W D Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-06       Impact factor: 4.254

Review 5.  Familial multiple myeloma: a family study and review of the literature.

Authors:  H T Lynch; W G Sanger; S Pirruccello; B Quinn-Laquer; D D Weisenburger
Journal:  J Natl Cancer Inst       Date:  2001-10-03       Impact factor: 13.506

6.  Familial clustering of ovarian and endometrial cancers.

Authors:  K Hemminki; C Granström
Journal:  Eur J Cancer       Date:  2004-01       Impact factor: 9.162

7.  DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma.

Authors:  Mark R Velangi; Elizabeth C Matheson; Gareth J Morgan; Graham H Jackson; Penelope R Taylor; Andrew G Hall; Julie A E Irving
Journal:  Carcinogenesis       Date:  2004-05-13       Impact factor: 4.944

8.  Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.

Authors:  D E Goldgar; D F Easton; L A Cannon-Albright; M H Skolnick
Journal:  J Natl Cancer Inst       Date:  1994-11-02       Impact factor: 13.506

9.  MSI in endometrial carcinoma: absence of MLH1 promoter methylation is associated with increased familial risk for cancers.

Authors:  Alison J Whelan; Sheri Babb; David G Mutch; Janet Rader; Thomas J Herzog; Christina Todd; Jennifer L Ivanovich; Paul J Goodfellow
Journal:  Int J Cancer       Date:  2002-06-10       Impact factor: 7.396

10.  Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer.

Authors:  Jennifer Ivanovich; Sheri Babb; Paul Goodfellow; David Mutch; Thomas Herzog; Janet Rader; Alison Whelan
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

View more
  3 in total

1.  Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer.

Authors:  Spyridon Marinopoulos; Lamprini Skorda; Stylianos Karatapanis; Antonis Rasidakis
Journal:  Med Oncol       Date:  2008-03-15       Impact factor: 3.064

2.  Familial myeloma.

Authors:  Henry T Lynch; Kelly Ferrara; Bart Barlogie; Elizabeth A Coleman; Jane F Lynch; Dennis Weisenburger; Warren Sanger; Patrice Watson; Henry Nipper; Vinetta Witt; Stephan Thomé
Journal:  N Engl J Med       Date:  2008-07-10       Impact factor: 91.245

3.  Epitope-positive truncating MLH1 mutation and loss of PMS2: implications for IHC-directed genetic testing for Lynch syndrome.

Authors:  Israel Zighelboim; Matthew A Powell; Sheri A Babb; Alison J Whelan; Amy P Schmidt; Mark Clendenning; Leigha Senter; Stephen N Thibodeau; Albert de la Chapelle; Paul J Goodfellow
Journal:  Fam Cancer       Date:  2009-08-12       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.